WHO – Page 16 – Communicable Diseases Research

Therapeutic strategies to fight COVID-19: Which is the status artis?

COVID-19와 싸우기 위한 치료 전략: 어떤 상태가 예술입니까?

Review

Published on 2022-05-012022-09-11
Journal: British Journal of Pharmacology [Category] COVID19(2023년), SARS, 신약개발, 치료제,

[키워드] Analysis anniversary anti-inflammatory drug Anticoagulants antiviral agent Antiviral agents approach approval article Clinical research clinical trials complex convalescent plasma Corticosteroids COVID COVID-19 Critically ill Critically ill patient disease drug Efficacy and safety European country Evidence Health Organization heparin heparins Hospitalized immunomodulatory investigated patients with COVID-19 pharmacological treatments phase Phase III clinical trials repurposing drugs review robust second wave supported The United States Treatment United States use of corticosteroid Vaccine Vaccines Vitamin D WHO World Health Organization
[DOI] 10.1111/bph.15452 PMC 바로가기 [Article Type] Review

Establishment of an in-house real-time RT-PCR assay for the detection of severe acute respiratory syndrome coronavirus 2 using the first World Health Organization international standard in a resource-limited country

자원이 제한된 국가에서 최초의 세계보건기구 국제표준을 이용한 중증급성호흡기증후군 코로나바이러스 2 검출을 위한 사내 실시간 RT-PCR 분석법 구축

Article

Published on 2022-05-012022-09-11
Journal: Journal of Clinical Laboratory Analysis [Category] COVID19(2023년), SARS, 치료기술, 치료제,

Emerging evidence on Omicron (B.1.1.529) SARS-CoV-2 variant

Omicron(B.1.1.529) SARS-CoV-2 변종에 대한 새로운 증거

Review

Published on 2022-05-012022-09-11
Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종,

Implication of in silico studies in the search for novel inhibitors against SARS-CoV-2

SARS-CoV-2에 대한 새로운 억제제를 찾기 위한 in silico 연구의 의미

Review

Published on 2022-05-012022-09-11
Journal: Archiv der Pharmazie [Category] COVID19(2023년), SARS, 변종, 치료제,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Ad26.COV2.S affected Antiviral antiviral drug antiviral phytoconstituents antiviral properties antiviral property approved AstraZeneca AZD1222 BBIBP-CorV Bharat BNT162b2 carried caused combating Corona CoronaVac coronavirus country COVID-19 COVID-19 infection database disease drug Drug administration effective effective vaccine Emergency use food Health Organization in silico in silico screening in vitro in vivo India individual inhibitor inhibitors inhibitors of SARS-CoV-2 janssen library Ligand Medicine Medicines Moderna molecular molecular docking mRNA mRNA-1273 Mutation occurred pandemic pandemic disease performed Pfizer/BioNTech plant plants PubChem Remdesivir researcher SARS-CoV-2 severe acute respiratory syndrome Coronavirus silico studies Sinopharm Sinovac Spread targets Treatment treatment of COVID-19 Vaccine Vaccines variants of SARS-CoV-2 Veklury WHO World Health Organization Wuhan Wuhan, China Zinc
[DOI] 10.1002/ardp.202100360 PMC 바로가기 [Article Type] Review

Timing the race of vaccination, new variants, and relaxing restrictions during COVID-19 pandemic

Research article

Published on 2022-05-012022-10-05
Journal: Journal of Computational Science [Category] 변종,

Computational studies on the interaction of SARS-CoV-2 Omicron SGp RBD with human receptor ACE2, limonin and glycyrrhizic acid

SARS-CoV-2 Omicron SGp RBD와 인간 수용체 ACE2, 리모닌 및 글리시리진산의 상호작용에 대한 전산 연구

Article

Published on 2022-05-012022-09-11
Journal: Computers in biology and medicine [Category] COVID19(2023년), SARS, 변종,

Implementation of HCV screening in the 1969-1989 birth-cohort undergoing COVID-19 vaccination

COVID-19 예방접종을 받는 1969-1989년 출생 코호트에서 HCV 스크리닝 실시

Article

Published on 2022-05-012022-09-12
Journal: Liver international : official journal of the Inte [Category] MERS, 진단,

An overview on inactivated and live-attenuated SARS-CoV-2 vaccines

불활성화 및 약독화 SARS-CoV-2 백신에 대한 개요

Review

Published on 2022-05-012022-09-11
Journal: Journal of Clinical Laboratory Analysis [Category] COVID19(2023년), SARS, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adverse effects antigenic attenuated vaccine benefit Bharat Cell culture Cellular immune response China clinical trials component components coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine deaths effective Efficiency Features followed by Health Organization humoral Humoral and cellular immune responses immune responses inactivated Inactivated vaccine Infection landscape Phase 3 produced producing Record report review Safe SARS-CoV-2 SARS-CoV-2 vaccine severe acute respiratory syndrome Coronavirus similarity Sinopharm Sinovac storage the vaccine Transport trials Vaccine vaccine candidate vaccine platform Vaccines virion virus particle WHO World Health Organization worldwide pandemic Wuhan
[DOI] 10.1002/jcla.24418 PMC 바로가기 [Article Type] Review

Genetic Sequence of Coronavirus Strains Isolated from Iraqi Patients and their Relationship with some Liver Enzymes and Interleukins

Article

Published on 2022-04-302022-11-15
Journal: Archives of Razi Institute [Category] COVID19(2023년), SARS, 치료기술,

[키워드] acute respiratory syndrome Admission Alpha ALT assigned AST asymptomatic patients Baghdad blood sample cause caused characterized coronavirus coronavirus disease correlation COVID-19 Deceased disease severity enzyme faster five group Genetic Genetic sequence genus Betacoronavirus groups hospitalized patient Il -10 Il- 18 IL-10 IL-18 Illumina indicated intensive care units interleukin Iraq isolate Isolated isolation hospital lactate dehydrogenase LDH less liver enzyme Ministry of Health moderate nasopharyngeal outcome polymerase chain positive sample positive-sense single-stranded RNA Public Quantitative relationship RT-PCR SARS-CoV-2 sequence severe symptom significantly Spread statistically significant strain TNF- α venous virulence virulent virus was determined WHO World Health Organization Wuhan Wuhan strain
[DOI] 10.22092/ARI.2022.357089.1967 PMC 바로가기

Clinical Improvement, Outcomes, Antiviral Activity, and Costs Associated With Early Treatment With Remdesivir for Patients With Coronavirus Disease 2019 (COVID-19)

코로나바이러스 감염증 2019(COVID-19) 환자를 위한 렘데시비르의 조기 치료와 관련된 임상 개선, 결과, 항바이러스 활성 및 비용

Article

Published on 2022-04-282022-09-11
Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), SARS, 진단, 치료제,

[키워드] activity addition Admission Antiviral antiviral activity benefit changes in changes in viral load clinical Clinical deterioration Clinical improvement clinical outcomes Control cost COVID-19 COVID-19 patients Disease progression Follow-up groups Hong Kong hospital discharge Hospital stay Hospitalized hospitalized patient hospitalized patients IgG antibody improvement In-hospital death Inconclusive intensive care invasive ventilation lower risk median Mild-to-moderate Moderate COVID-19 multiple imputation on admission outcome oxygen Oxygen therapy Patient patients with COVID-19 positive progression Remdesivir retrospective cohort risk significantly shorter study outcomes the disease time Treatment Viral viral clearance Viral load WHO
[DOI] 10.1093/cid/ciab631 PMC 바로가기 [Article Type] Article